Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BLd induction, ASCT, DLd consolidation, and lenalidomide maintenance in transplant-eligible newly diagnosed multiple myeloma
jRCTs051200043Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib, lenalidomide, dexamethasone, daratumumab, melphalan and 2 more in multiple myeloma (MM), sponsored by Bristol Myers Squibb. Primary endpoint: Complete response rate before maintenance therapy. Started Sep 2020; status: completed.
02
Drugs
bortezomiblenalidomidedexamethasonedaratumumabmelphalan
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCTs051200043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051200043.